Netupitant and Palonosetron
- Generic Name
- Netupitant and Palonosetron
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗与癌症化疗相关的恶心和呕吐。
- Associated Conditions
- -
- Associated Therapies
- -
Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
Phase 2
Terminated
- Conditions
- Chemotherapy Induced Nausea Vomiting
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Joseph Ma
- Target Recruit Count
- 4
- Registration Number
- NCT03008213
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Phase 3
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 413
- Registration Number
- NCT01376297
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
🇺🇸East Valley Hematology and Oncology Medical Group, Burbank, California, United States
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Phase 3
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 1455
- Registration Number
- NCT01339260
- Locations
- 🇺🇸
Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸The John R Marsh Cancer Center, Hagerstown, Maryland, United States
🇺🇸Compassionate Cancer Centre Medical Group, Fountain Valley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath